OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
New biotherapeutics both drive and benefit from innovative development technologies.
FDA releases some J&J vaccines from Emergent facility; EU puts release on hold
Complex formulations, personalized medicines, and more are driving innovations in drug packaging.
A task force establishes scientific data for integrity test activities.
Automation offers benefits for sterile manufacturing in 503B facilities.
June 21, 2021
The guidance provides recommendations for including premenopausal women in breast cancer clinical trials.
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
Exscientia has entered into a binding agreement to acquire the artificial intelligence precision-based medicines company, Allcyte.
RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for seronegative hospitalized patients with severe COVID-19.
June 18, 2021
CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis.
The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.
GlaxoSmithKline and iTeos Therapeutics enter into a development and commercialization collaboration worth up to $2.08 billion for a new therapeutic anti-cancer mAb candidate.
Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
BIA has published a report presenting the findings of a survey on the public attitudes toward equal access to medicines for those living with rare diseases.
Horiba has joined a consortium aimed at accelerating the development of process analytical technologies for cell and gene therapy manufacturing